UNSPSC 51132307: Idarucizumab

The monoclonal antibody used as reversal anti-coagulant effects of dabigatran.

UNSPSC 51132307 Idarucizumab, a Commodity code, represents a specific pharmaceutical antidote procured by state and local health systems and emergency medical services. Idarucizumab is a monoclonal antibody fragment used to reverse the anticoagulant effects of dabigatran in bleeding patients, typically sourced through pharmaceutical wholesalers or direct manufacturer contracts. State and local purchasers—primarily hospital systems, county health departments, and emergency medical services agencies—acquire this drug for emergency department and intensive care unit stock, often through cooperative purchasing agreements or state pharmaceutical formulary programs.

The source provided contains no recent state or local contract opportunities tagged to this code, preventing characterization of geographic spread, issuing-body concentration, or representative recent solicitations. This silence suggests either sparse procurement activity under the code at the state and local level, heavy consolidation through state health-system cooperative frameworks that do not issue individual RFPs or RFQs for pharmaceutical line items, or misalignment between how purchasing agencies tag pharmaceutical acquisitions and this UNSPSC classification. Validation through state pharmaceutical directory searches, health system group purchasing organization (GPO) contracts, or direct contact with state health department procurement offices would clarify whether demand exists and how purchasing typically flows.